Cyclo Therapeutics, Inc.
CYTH
$0.7206
$0.00991.39%
| Weiss Ratings | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.39 | |||
| Price History | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 7.63% | |||
| 30-Day Total Return | -30.71% | |||
| 60-Day Total Return | 19.80% | |||
| 90-Day Total Return | 17.23% | |||
| Year to Date Total Return | 20.10% | |||
| 1-Year Total Return | -48.16% | |||
| 2-Year Total Return | -20.34% | |||
| 3-Year Total Return | -73.80% | |||
| 5-Year Total Return | -97.01% | |||
| 52-Week High % Change | -- | |||
| 52-Week Low % Change | -- | |||
| Price | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.79 | |||
| 52-Week Low Price | $0.55 | |||
| 52-Week Low Price (Date) | Dec 31, 2024 | |||
| 52-Week High Price (Date) | Apr 02, 2024 | |||
| Valuation | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 20.73M | |||
| Enterprise Value | 32.01M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.92 | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 23.78 | |||
| Price/Book (Q) | -1.54 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.72 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 28.73M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 386 418 8060 | |||
| Address | 6714 NW 16th Street Gainesville, FL 32653 | |||
| Website | cyclotherapeutics.com | |||
| Country | United States | |||
| Year Founded | 1990 | |||
| Profitability | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -2,833.80% | |||
| Profit Margin | -2,847.92% | |||
| Management Effectiveness | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -284.27% | |||
| Return on Equity | -- | |||
| Income Statement | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 870.80K | |||
| Total Revenue (TTM) | 870.80K | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 794.60K | |||
| EBITDA (TTM) | -24.67M | |||
| EBIT (TTM) | -24.68M | |||
| Net Income (TTM) | -24.80M | |||
| Net Income Avl. to Common (TTM) | -24.80M | |||
| Total Revenue Growth (Q YOY) | -52.82% | |||
| Earnings Growth (Q YOY) | -85.12% | |||
| EPS Diluted (TTM) | -0.92 | |||
| EPS Diluted Growth (Q YOY) | -4.34% | |||
| Balance Sheet | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 928.00K | |||
| Cash Per Share (Q) | $0.03 | |||
| Total Current Assets (Q) | 3.26M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -13.47M | |||
| Current Ratio (Q) | 0.174 | |||
| Book Value Per Share (Q) | -$0.47 | |||
| Total Assets (Q) | 5.25M | |||
| Total Current Liabilities (Q) | 18.72M | |||
| Total Debt (Q) | 12.21M | |||
| Total Liabilities (Q) | 18.73M | |||
| Total Common Equity (Q) | -13.47M | |||
| Cash Flow | CYTH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.40K | |||
| Cash from Financing (TTM) | 21.65M | |||
| Net Change in Cash (TTM) | -873.80K | |||
| Levered Free Cash Flow (TTM) | -13.58M | |||
| Cash from Operations (TTM) | -22.52M | |||
